MTOR and breast carcinoma: For example, a top hit in our screen, RPS6KB1, is downstream of mTOR and PI3K, two prominent signaling pathways in breast cancer with known direct inhibitors, rapamycin and LY294002, and that have been shown to sensitize cells to paclitaxel [59,70].